🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPharmacology & MechanismsHas anyone dealt with glp-1r expression map?

Has anyone dealt with glp-1r expression map?

mike_mod Fri, Oct 18, 2024 at 7:09 PM 35 replies 1,913 viewsPage 1 of 7
This thread is more than 19 months old. Information may be outdated. Consider searching for more recent discussions.
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Oct 18, 2024 at 7:09 PM#1

This gets cited here weekly, usually second-hand, so it is worth setting out what it does and does not establish.

The pharmacokinetics explain nearly every practical question asked here. Albumin binding above 99% slows clearance enough to make weekly dosing possible; a terminal half-life near a week means four to five weeks to steady state and therefore a four-week titration interval; subcutaneous bioavailability around 89% means injection site barely matters. Those three facts answer most timing questions before they are asked.

Where I think it is weakest: the population was selected and supported in ways a real cohort is not, so I would read the effect size as a ceiling rather than an expectation.

So the question, as narrowly as I can put it: which effects tachyphylax and which persist, because the answer explains why tolerability improves while the appetite effect keeps working. Numbers rather than impressions, if you have them.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
2 22PharmHunterJen, TomTeleRx
Reply Quote Save Share Report
SarahChen_PharmD
VIP Member
4,567
22,341
Dec 2023
San Diego, CA
Oct 18, 2024 at 7:16 PM#2
mike_mod said:
The pharmacokinetics explain nearly every practical question asked here.

Pharmacist here. I want to add the drug interaction perspective on the pharmacology.

Key points from a pharmacokinetic standpoint:

  • GLP-1 agonists delay gastric emptying, which can affect Tmax of co-administered oral medications
  • Monitor patients on warfarin (INR), levothyroxine (TSH), and oral contraceptives during dose titration
  • The albumin-binding mechanism of semaglutide (C-18 fatty acid linker) gives it the ~168-hour half-life that enables weekly dosing
  • Steady state is reached at approximately 4-5 weeks after dose initiation or adjustment

Re: the pharmacology specifically — the pharmacology here is well-characterized and the clinical implications are straightforward.

1 21NurseKim_ATL
Reply Quote Save Share Report
Dr.SleepRoch
Senior Member
1,123
5,678
Apr 2024
Rochester, MN
Oct 18, 2024 at 7:23 PM#3
mike_mod said:
The pharmacokinetics explain nearly every practical question asked here.

This is where I part company with the consensus forming above. The mechanism is more central than most summaries suggest. Receptor agonism in the arcuate nucleus activates POMC neurons and inhibits AgRP/NPY signalling, and the downstream MC4R pathway is the same one disrupted in monogenic obesity — convergent genetic evidence that the target is the right one. Peripherally there is glucose-dependent insulin secretion, glucagon suppression and delayed gastric emptying, but the gastric component largely adapts over months while the central effect persists, which is why the durable effect is appetite rather than fullness.

Last edited: Oct 18, 2024 at 11:23 PM
50 20Dr.NephBHM_UK, kim_atl_prep, sarah_TO and 47 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
roxy_nash
Member
178
890
Dec 2024
Nashville, TN
Oct 18, 2024 at 7:30 PM#4
Dr.SleepRoch said:
The mechanism is more central than most summaries suggest.

Receptor pharmacology relevant to the pharmacology: semaglutide is a GLP-1R agonist with a C-18 fatty acid chain that enables albumin binding (>99%), creating a depot effect with a ~168-hour half-life enabling weekly dosing[1].

Tirzepatide is a dual GIP/GLP-1R agonist with higher GIP affinity (5:1 GIP:GLP-1 potency ratio). The GIP component may enhance beta-cell function and adipocyte lipid metabolism beyond what GLP-1 alone achieves.

For the pharmacology, the pharmacology explains the clinical differences between these agents.

References:
[1] Lau J, et al. J Med Chem. 2015;58(18):7370-7380.
49 19Dr.NephBHM_UK, kim_atl_prep, sarah_TO and 46 others
Reply Quote Save Share Report
CryptoCarl
Member
789
3,456
May 2024
Arizona
Oct 18, 2024 at 8:07 PM#5
SarahChen_PharmD said:
I want to add the drug interaction perspective on the pharmacology.

Second this.

48 18ChrisMacros, KetoKyle, CanadaChris and 45 others
Reply Quote Save Share Report
1237

Similar Threads

GLP-1R desensitization — β-arrestin-mediated internalization18 replies
Biased agonism at GLP-1R — Gs vs β-arrestin signaling balance13 replies
Semaglutide albumin binding and the C-18 fatty acid linker17 replies
GIP receptor pharmacology — why GIP agonism enhances GLP-113 replies
Glucagon receptor signaling — hepatic glycogenolysis and lipolysis16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register